Barclays maintains Jazz Pharmaceuticals at Overweight
Barclays maintained its Overweight rating on Jazz Pharmaceuticals, according to Benzinga’s ratings-actions roundup. No price target change or additional details were provided in the feed.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.